For example, apoC-II activates the enzyme lipoprotein lipase (LPL), which removes TG from lipoprotein particles such as chylomicrons and VLDL. Each lipoprotein class (chylomicrons, VLDL ...

CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...

CTX-310 targets ANGPTL3, which is an enzyme which breaks down lipoprotein lipase. And essentially, if you inhibit ANGPTL3, you have more lipoprotein lipase to get rid of lipoproteins that are in ...

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a ... drug against a third cardiovascular disease target – ANGPTL3 – to Pfizer in 2019 in a deal that included ...

aDepartment of Clinical Biochemistry, Copenhagen University Hospital - Herlev and Gentofte, Denmark bThe Copenhagen General Population Study, Copenhagen University Hospital - Herlev and Gentofte, ...

Patrick Trucchio; Analyst; H.C. Wainwright. Mayank Mamtani; Analyst; B. Riley Securities. I will now hand the conference over to Vince Anzalone, Vice President of Investor Relations of Arrowhead ...

Background: Multiple guidelines recommend detection of and early risk factor management for elevated lipoprotein(a) [Lp(a)]. Effective implementation requires assessment of knowledge and practices ...

Patrick Trucchio; Analyst; H.C. Wainwright. Mayank Mamtani; Analyst; B. Riley Securities. I will now hand the conference over to Vince Anzalone, Vice President of Investor Relations of Arrowhead.